Skip to main content

We are proud to announce that our recent manuscript has been accepted for publication in the journal Vaccine. The manuscript describes the development of a low-cost manufacturing process for a novel human rotavirus vaccine. 

Rotavirus infection, associated with severe vomiting and diarrhea, is a leading cause of mortality in young children. Despite the presence of several licensed vaccines, coverage in low-income countries remains a concern. Currently, it is estimated that more than 88 million infants per year are unvaccinated against the rotavirus. One of the major barriers to global implementation of the current rotavirus vaccines is price. The target for such vaccines in low-income countries is their production at a Cost-of-Goods of approximately $3-4 per course or less. The prices of the currently marketed vaccines are well beyond this target. Our manuscript describes the development of a low-cost manufacturing process that delivers a stable liquid human rotavirus vaccine at the target Cost-of-Goods.

About the RV3-BB vaccine

The RV3-BB human neonatal rotavirus vaccine was developed at the Murdoch Children’s Research Institute. The live-attenuated vaccine candidate provides protection from severe rotavirus disease from birth. Due to an earlier peak age of disease in high-mortality settings, the vaccine is tested in a neonatal schedule. In a recent randomized placebo-controlled efficacy study conducted in Central Java and Yogyakarta, Indonesia, three doses of RV3-BB in Indonesian infants resulted in 75% efficacy against severe rotavirus gastroenteritis in the first 18 months of life when administered in a neonatal schedule. This is a significantly higher efficacy than that seen with currently marketed rotavirus vaccines.

This project was funded by a grant from the Bill & Melinda Gates Foundation (#OPP1148427) aimed to accelerate the development of a low-cost, liquid RV3-BB rotavirus vaccine for Gavi-eligible countries through formulation development and bulk process optimization.

Link to full article.